Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
- PMID: 15791453
- DOI: 10.1007/s00280-004-0976-x
Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
Abstract
We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) would be modulated by agents targeting epigenetics in oral cancer cell lines. Although hTERT is known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting epigenetics work on hTERT transcription. In the present study, the epigenetic effects of the histone deacetylase (HDAC) inhibitor FR901228 on hTERT transcription in oral cancer cell lines were analyzed by RT-PCR. The mRNA expression of hTERT was upregulated after exposure to FR901228 in hTERT-negative Hep2 cells, and even SAS and KB cells expressed high levels of hTERT. Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228. This suggests that the induction of hTERT by FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an indirect effect on epigenetic changes such as histone acetylation/deacetylation. We further examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription activators. FR901228 repressed c-myc protein only in the absence of CHX, and depended on the enhancement of de novo protein synthesis. Our results indicate that c-myc protein is repressed indirectly by FR901228 but may not contribute to FR901228-induced hTERT transcription. The present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex mechanism that involved transcription factors other than c-myc, in addition to inhibition of histone deacetylation.
Similar articles
-
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.J Urol. 2005 Aug;174(2):747-52. doi: 10.1097/01.ju.0000164723.20555.e6. J Urol. 2005. PMID: 16006969
-
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.Exp Cell Res. 2006 Feb 1;312(3):256-65. doi: 10.1016/j.yexcr.2005.10.026. Epub 2005 Dec 13. Exp Cell Res. 2006. PMID: 16356494
-
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.Exp Cell Res. 2002 Mar 10;274(1):25-34. doi: 10.1006/excr.2001.5462. Exp Cell Res. 2002. PMID: 11855854
-
Histone deacetylase inhibition as an anticancer telomerase-targeting strategy.Int J Cancer. 2011 Dec 15;129(12):2765-74. doi: 10.1002/ijc.26241. Epub 2011 Aug 8. Int J Cancer. 2011. PMID: 21671468 Review.
-
Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms.Front Genet. 2016 May 9;7:83. doi: 10.3389/fgene.2016.00083. eCollection 2016. Front Genet. 2016. PMID: 27242892 Free PMC article. Review.
Cited by
-
Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation.Curr Cancer Drug Targets. 2018;18(1):97-106. doi: 10.2174/1568009617666170206104032. Curr Cancer Drug Targets. 2018. PMID: 28176652 Free PMC article.
-
Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review.Cancers (Basel). 2023 Nov 27;15(23):5600. doi: 10.3390/cancers15235600. Cancers (Basel). 2023. PMID: 38067304 Free PMC article. Review.
-
Epigenetics in oral squamous cell carcinoma.J Oral Maxillofac Pathol. 2017 May-Aug;21(2):252-259. doi: 10.4103/jomfp.JOMFP_150_17. J Oral Maxillofac Pathol. 2017. PMID: 28932035 Free PMC article. Review.
-
Epigenetic disregulation in oral cancer.Int J Mol Sci. 2012;13(2):2331-2353. doi: 10.3390/ijms13022331. Epub 2012 Feb 21. Int J Mol Sci. 2012. PMID: 22408457 Free PMC article. Review.
-
Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma.J Oncol. 2023 Feb 9;2023:4616682. doi: 10.1155/2023/4616682. eCollection 2023. J Oncol. 2023. PMID: 39282225 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical